Galapagos (GLPG) Projected to Post Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, July 23rd. Analysts expect Galapagos to post earnings of ($0.34) per share and revenue of $80.13 million for the quarter.

Galapagos (NASDAQ:GLPG) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($2.24). The firm had revenue of $97.33 million for the quarter, compared to analyst estimates of $72.22 million. On average, analysts expect Galapagos to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Galapagos Trading Down 0.8%

GLPG stock opened at $30.27 on Wednesday. The firm has a 50 day moving average of $28.25 and a 200 day moving average of $26.32. Galapagos has a 52 week low of $22.36 and a 52 week high of $31.23.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut shares of Galapagos from a “hold” rating to a “sell” rating in a research note on Friday, April 25th. Five research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $25.33.

Hedge Funds Weigh In On Galapagos

An institutional investor recently raised its position in Galapagos stock. Jane Street Group LLC grew its position in shares of Galapagos NV (NASDAQ:GLPG) by 2,245.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,783 shares of the biotechnology company’s stock after purchasing an additional 115,946 shares during the quarter. Jane Street Group LLC owned approximately 0.17% of Galapagos worth $2,783,000 as of its most recent SEC filing. 32.46% of the stock is owned by hedge funds and other institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.